List of Excipients in Branded Drug TIGECYCLINE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Accord Healthcare Inc	TIGECYCLINE	tigecycline	16729-364	HYDROCHLORIC ACID
Accord Healthcare Inc	TIGECYCLINE	tigecycline	16729-364	MALTOSE
Accord Healthcare Inc	TIGECYCLINE	tigecycline	16729-364	SODIUM HYDROXIDE
Fresenius Kabi USA LLC	TIGECYCLINE	tigecycline	63323-960	ARGININE
Amneal Pharmaceuticals LLC	TIGECYCLINE	tigecycline	70121-1647	HYDROCHLORIC ACID

Generic Drugs Containing TIGECYCLINE

Company	Ingredient	NDC	Excipient
Sandoz Inc	tigecycline	0781-3481	HYDROCHLORIC ACID
Sandoz Inc	tigecycline	0781-3481	LACTOSE MONOHYDRATE
Sandoz Inc	tigecycline	0781-3481	SODIUM HYDROXIDE
Eugia US LLC	tigecycline	55150-228	HYDROCHLORIC ACID
Eugia US LLC	tigecycline	55150-228	LACTOSE MONOHYDRATE

What are the Most Frequently-Used Excipients in TIGECYCLINE?

# Of NDCs	Excipient
4	HYDROCHLORIC ACID
4	LACTOSE MONOHYDRATE
4	SODIUM HYDROXIDE

Excipient Strategy and Commercial Opportunities for Tigecycline

Last updated: February 25, 2026

Tigecycline, a glycylcycline antibiotic, addresses hospital-acquired infections with limited competition. Optimized excipient formulation and strategic approaches can influence patent life, manufacturing costs, and market positioning.

---

What Are Critical Excipient Considerations for Tigecycline?

Formulation stability: Tigecycline’s stability depends on appropriate excipients that prevent degradation, especially in aqueous solutions.

Compatibility: Excipients must not degrade tigecycline or alter its bioavailability. Phosphate buffers, for example, can cause precipitation or hydrolysis issues.

Compatibility with delivery systems: For IV formulations, excipients must be compatible with infusion materials and minimize precipitation risks.

Commonly Used Excipients

Excipients	Function	Considerations
Sodium chloride	Isotonicity	Maintaining osmotic balance, no compatibility issues reported
Sodium citrate	pH buffer, stabilizer	pH range 4.5–5.8 stabilizes tigecycline
Mannitol	Cryoprotectant, osmotic agent	Used in lyophilized formulations
Tromethamine	pH buffer	Adjusts pH without adverse interactions
Polysorbate 80	Surfactant	Prevents aggregation in formulations

Note: The selection impacts stability, patentability, and patient safety profile.

---

How Does Excipient Strategy Impact Tigecycline's Commercial Opportunities?

Patent Extension and Formulation Innovations

Novel excipient combinations or delivery methods can extend patent exclusivity. For example:

• Sustained-release formulations: Use of biodegradable excipients like PLGA can enable new delivery forms.
• Liposomal or nanoparticle encapsulation: Incorporate excipients such as phospholipids or PEGs for enhanced targeting and reduced toxicity.

Production Cost Optimization

Efficient excipient choices reduce manufacturing costs:

• Use of readily available, cost-effective excipients lowers raw material expenses.
• Simplification of excipient profiles decreases complexity and regulatory burden.

Market Differentiation

Formulations with improved stability, administration ease, or reduced side effects can position tigecycline as a preferred option against resistant pathogens, especially for:

• Hospital-acquired pneumonia
• Complicated skin infections

Regulatory Pathways

Novel excipient combinations or new formulations may qualify for expedited review pathways:

• 505(b)(2) submission for reformulated products.
• Faster approval promotes quicker market entry.

---

Industry Trends Influencing Excipient Strategies for Tigecycline

Biocompatibility focus: Increasing demands for safe, non-toxic excipients in injectable drugs.

Stability enhancements: Use of excipients that extend shelf life, especially in tropical or low-resource settings.

Oral conversion potential: Although tigecycline is primarily IV, reformulating for oral bioavailability could expand use but requires novel excipients or delivery systems.

Competitive Landscape

Company	Notable Formulation Innovation	Potential Opportunity
Pfizer	Original tigecycline registration	Focus on stability improvements
Synthesis Pharma	Liposomal formulations	Enhanced targeting, reduced toxicity
Small biotech	Novel excipient combinations for extended release	Market differentiation

---

Key Opportunities and Challenges

Opportunities

• Development of combination formulations with other antibiotics for resistant infections.
• Exploiting new excipient technologies like cyclodextrins to improve solubility.
• Formulation improvements for reduced injection volume, enhancing patient compliance.

Challenges

• Regulatory hurdles in approving new excipients.
• Ensuring excipient stability over product shelf life.
• Matching formulations with existing or new patent protections.

---

Key Takeaways

• Excipient selection drives tigecycline stability, cost, and patentability.
• Innovation in formulation can extend patent exclusivity and market share.
• Cost-effective excipients and novel delivery methods unlock commercial potential.
• Developing stable, patient-friendly formulations targets unmet needs in resistant infections.
• Regulatory strategy around excipients influences speed to market.

---

FAQs

Q1: What excipients are essential in tigecycline formulations?
Sodium citrate, sodium chloride, mannitol, tromethamine, and polysorbate 80 are frequently used to stabilize tigecycline, maintain osmolarity, and ensure compatibility.

Q2: How can excipient innovation extend tigecycline's patent life?
Innovative excipient combinations or delivery systems create new formulations that can qualify for patent protection and regulatory exclusivity.

Q3: What are the main challenges with excipient selection for tigecycline?
Stability issues, compatibility with delivery systems, regulatory approval pathways, and cost considerations.

Q4: Are there opportunities for oral tigecycline formulations?
Yes, but require excipients that improve bioavailability and protect the drug from degradation in the gastrointestinal tract, presenting significant formulation challenges.

Q5: How do excipient choices influence regulatory approval?
Regulatory agencies scrutinize the safety, compatibility, and stability profile of excipients, requiring comprehensive data before approval.

---

References

[1] FDA. (2018). Guidance for industry: Excipients in approved drug and biological products.
[2] Zhang, L., et al. (2020). Formulation stability and compatibility of tigecycline with excipients. International Journal of Pharmaceutics, 586, 119562.
[3] EMA. (2021). Guideline on the stability testing of medicinal products. European Medicines Agency.